APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 811.20

Change

+4.60 (+0.57)%

Market Cap

INR 159.45B

Volume

0.30M

Avg Analyst Target

INR 1,025.00 (+26.36%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (API) and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, anti-diabetic, gynecology, acute, gastroenterology, ophthalmology, dermatology, nephrology/urology, orthopedics, cancer, inflammation, autoimmune diseases, anti-infective, cold and cough, and metabolic disorders, as well as hospital care and animal health. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India. Address: Alembic Road, Vadodara, India, 390003

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-5.40 (-0.64%)

INR2,005.60B 33.44 21.56
DIVISLAB:NSE Divi's Laboratories Limited

-29.10 (-0.54%)

INR1,418.41B 69.21 43.47
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-81.20 (-1.64%)

INR809.18B 47.29 21.18
PEL:NSE Piramal Enterprises Limited

-19.00 (-0.67%)

INR672.50B 48.98 11.87
CADILAHC:NSE Cadila Healthcare Limited

-9.80 (-1.80%)

INR547.09B 24.12 17.94
ALKEM:NSE Alkem Laboratories Limited

-31.40 (-0.81%)

INR461.68B 28.31 21.09
LUPIN:NSE Lupin Limited

-10.00 (-1.06%)

INR425.18B 25.81 14.15
AUROPHARMA:NSE Aurobindo Pharma Limited

-8.90 (-1.22%)

INR420.85B 7.90 5.01
LAURUSLABS:NSE Laurus Labs Limited

-5.85 (-0.90%)

INR346.19B 33.02 21.30
IPCALAB:NSE Ipca Laboratories Limited

-6.60 (-0.27%)

INR306.42B 30.59 20.49

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.19% 9% F 4% F
Dividend Return 1.34% 95% A 61% D-
Total Return -20.85% 9% F 5% F
Trailing 12 Months  
Capital Gain -16.59% 11% F 4% F
Dividend Return 1.44% 79% C+ 51% F
Total Return -15.16% 11% F 4% F
Trailing 5 Years  
Capital Gain 20.37% 37% F 47% F
Dividend Return 4.08% 80% B- 50% F
Total Return 24.45% 37% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 17.74% 49% F 61% D-
Dividend Return 0.65% 72% C- 48% F
Total Return 18.38% 48% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 35.54% 78% C+ 76% C
Risk Adjusted Return 51.72% 68% D+ 80% B-
Market Capitalization 159.45B 82% B- 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.25 70% C- 64% D
Price/Book Ratio 3.14 60% D- 37% F
Price / Cash Flow Ratio 10.90 64% D 45% F
EV/EBITDA 11.74 72% C- 56% F
Management Effectiveness  
Return on Equity 27.77% 90% A- 93% A
Return on Invested Capital 21.77% 81% B- 91% A-
Return on Assets 12.77% 82% B- 93% A
Debt to Equity Ratio 3.90% 56% F 67% D+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.73 52% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector